TNFRSF10A and Miyoshi myopathy: Two human agonistic mAbs directed against TRAILR1 (HGS-ETR1, TRM-1, Mapatumumab) and TRAILR2 (HGS-ETR2) killed 68% and 45% of MM cell lines, respectively, [48].